SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Nvidia Partners With Fanuc and Yaskawa to Accelerate AI Robotics in Japan 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
Alibaba Stock Jumps as China Approves Apple Intelligence Powered by Qwen AI 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
TEL AVIV, Israel, Feb. 01, 2016 -- VBL Therapeutics (NASDAQ:VBLT), announced today that Chief Executive Officer, Dror Harats, M.D., will provide a corporate overview and business update at the BIO CEO & Investor Conference.
| Presentation Details: | |
| Title: | The 18th Annual BIO CEO & Investor Conference |
| Date: | February 9th, 2016 |
| Time: | 11:30-11:55 AM |
| Location: | The Waldorf Astoria New York |
| Webcast: | http://www.veracast.com/webcasts/bio/ceoinvestor2016/47215257222.cfm |
About VBL
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma (rGBM), an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics' pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment granted by the FDA.
INVESTOR CONTACT: Michael Rice, Founding Partner LifeSci Advisors, LLC 646-597-6979
